Novartis signals growing ambitions for cancer therapies
Drugmaker is planning to test its CAR-T treatments on lethal cancers of the brain, pancreas, colon, ovary and lung
London
NOVARTIS AG is pushing ahead with one of its most ambitious cancer therapies, a treatment that the Swiss drugmaker says has blockbuster potential as it extends that technology to a wider pool of tumour-ridden patients.
Europe's second-biggest drugmaker is planning to test its CAR-T treatments - which involve extracting immune cells and genetically engineering them to hunt and kill cancer cells before returning them into the patient's body - on lethal cancers of the brain, pancreas, colon, ovary and lung. The company has also doubled its investment in manufacturing for these treatments.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO